A phase 2 trial exploring the significance of homologous recombination status in patients with platinum sensitive or platinum resistant relapsed ovarian cancer receiving combination cediranib and olaparib
Year: 2024
Type: article
Study design: Clinical Trial
Source: Gynecologic Oncology
Authors: Joyce F. Liu, Niya Xiong, Robert M. Wenham, Andrea Wahner-Hendrickson, Deborah K. Armstrong, Nancy Chan, David M. O'Malley, Jung-Min Lee, Richard T. Penson, Mihaela C. Cristea, James L. Abbruzzese, Koji Matsuo, Alexander B. Olawaiye, William T. Barry, Su-Chun Cheng, Madeline Polak, Elizabeth M. Swisher, Geoffrey I. Shapiro, Elise C. Kohn, S. Percy Ivy, Ursula A. Matulonis
Institutions: Dana-Farber Cancer Institute, Dana-Farber/Harvard Cancer Center, Moffitt Cancer Center, Mayo Clinic, Johns Hopkins University, Johns Hopkins Hospital, Sidney Kimmel Comprehensive Cancer Center, Rutgers Cancer Institute, The Ohio State University, National Cancer Institute, Center for Cancer Research, Massachusetts General Hospital, City Of Hope National Medical Center, City of Hope, Duke University, Duke Cancer Institute, University of Southern California, University of Pittsburgh Medical Center, University of Washington, National Institutes of Health
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W4397004749